Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology.

{"article_title":"Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology.","author":"Bonovas S, Piovani D, Pansieri C, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A","journal_title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","issn":"1878-3562","isbn":"","publication_date":"2023-06-01","volume":"55","issue":"6","first_page":"695","page_count":"","accession_number":"36964060","doi":"10.1016\/j.dld.2023.02.019","publisher":"Elsevier","doctype":"Systematic Review","subjects":"Crohn Disease drug therapy; Biological Products therapeutic use; Adult; Humans; Infliximab therapeutic use; Adalimumab therapeutic use; Ustekinumab therapeutic use","interest_area":["Gastroenterology"],"abstract":"The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Several biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD. This technical review systematically searched and identified the current evidence, synthesized it using meta-analytic methodology, appraised its quality, and concisely presented it, thus forming the basis for developing clinical practice recommendations on the use of biologic treatments in adult patients with CD. Competing Interests: Conflict of interest Fabio Macaluso has served as an advisory board member and\/or received lecture grants from AbbVie, Biogen, Ferring, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda. Ambrogio Orlando has served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda, and received lecture fees from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda. Stefano Festa has served as an advisory board member for Janssen Cilag, and received consultancy fees and\/or educational grants from Takeda, SoFar, Abbvie, Pfizer, and Zambon. Claudio Papi has received consultancy fees and\/or educational grants from Abbvie, MSD, Takeda, Pfizer, Janssen-Cilag, Sandoz, Chiesi, Sofar, Ferring, and Zambon. Daniela Pugliese has served as an advisory board member for Janssen Cilag, Pfizer, and received consultancy fees and\/or educational grants from Takeda, Janssen Cilag, Pfizer, and Galapagos. Alessandro Armuzzi has received consulting and\/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist-Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; lecture and\/or speaker bureau fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix, and research grants from MSD, Pfizer, Takeda, and Biogen. Stefanos Bonovas, Daniele Piovani and Claudia Pansieri have no conflicts of interest to declare. Copyright \u00a9 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36964060","isPdfLink":false,"isSAML":false,"an":"36964060","number_other":"","type_pub":"","issn_electronic":"1878-3562","languages":"English","language":"eng","date_entry":"Date Created: 20230324 Date Completed: 20230529 Latest Revision: 20230720","date_update":"20240104","titleSource":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2023 Jun; Vol. 55 (6), pp. 695-703. Date of Electronic Publication: 2023 Mar 22.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2023-06-01","description":"The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Several biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD. This technical review systematically searched and identified the current evidence, synthesized it using meta-analytic methodology, appraised its quality, and concisely presented it, thus forming the basis for developing clinical practice recommendations on the use of biologic treatments in adult patients with CD.<br \/>Competing Interests: Conflict of interest Fabio Macaluso has served as an advisory board member and\/or received lecture grants from AbbVie, Biogen, Ferring, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda. Ambrogio Orlando has served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda, and received lecture fees from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda. Stefano Festa has served as an advisory board member for Janssen Cilag, and received consultancy fees and\/or educational grants from Takeda, SoFar, Abbvie, Pfizer, and Zambon. Claudio Papi has received consultancy fees and\/or educational grants from Abbvie, MSD, Takeda, Pfizer, Janssen-Cilag, Sandoz, Chiesi, Sofar, Ferring, and Zambon. Daniela Pugliese has served as an advisory board member for Janssen Cilag, Pfizer, and received consultancy fees and\/or educational grants from Takeda, Janssen Cilag, Pfizer, and Galapagos. Alessandro Armuzzi has received consulting and\/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist-Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; lecture and\/or speaker bureau fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix, and research grants from MSD, Pfizer, Takeda, and Biogen. Stefanos Bonovas, Daniele Piovani and Claudia Pansieri have no conflicts of interest to declare.<br \/> (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=36964060&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Bonovas S, Piovani D, Pansieri C, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A"}